Introducing REYOBIQ™

by | Mar 20, 2025 | GBM, LM, PBC, Uncategorized

Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...

Advancing Treatment for Leptomeningeal Metastases

by | Mar 17, 2025 | LM

Advancing Treatment for Leptomeningeal Metastases (LM): ReSPECT-LM Clinical Trial Now Enrolling Leptomeningeal metastases (LM) is a devastating complication of cancer, occurring when malignant cells spread to the cerebrospinal fluid (CSF) and leptomeninges, leading to...

Nature Publication

by | Mar 7, 2025 | GBM

Phase 1 Clinical Trial Results for Rhenium (186Re) Obisbemeda in Recurrent Glioblastoma (GBM) Now in Nature Communications 📢 Exciting News! The results of our Phase 1 clinical trial for Rhenium (186Re) Obisbemeda in recurrent glioblastoma (GBM) have been published in...

LM ODD for Lung Cancer Patients

by | Mar 6, 2025 | LM

FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Lung Cancer Patients with Leptomeningeal Metastases We are thrilled to announce that the U.S. FDA has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of...

Advancing Treatment for Recurrent Glioblastoma

by | Mar 2, 2025 | GBM

ReSPECT-GBM Clinical Trial: Advancing Treatment for Recurrent Glioblastoma (GBM) Glioblastoma (GBM) is one of the most aggressive and treatment-resistant brain cancers, with limited therapeutic options available for patients with recurrent disease. The ReSPECT-GBM...